

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

BRD4 Recombinant Monoclonal Antibody [BL-149-2H5]

RRID:AB_2631885

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# A700-004, RRID:AB_2631885

Antibody Information

URL: http://antibodyregistry.org/AB_2631885

Proper Citation: Thermo Fisher Scientific Cat# A700-004, RRID:AB_2631885

Target Antigen: BRD4

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued; Applications: ICC (1:25-1:250), IP (5-20 µL/0.5 mg lysate), IHC (1:25-1:250), ChIP-seq (10-40 µL/30 µg chromatin), WB (1:1,000), IF (1:25-1:250)

Antibody Name: BRD4 Recombinant Monoclonal Antibody [BL-149-2H5]

Description: This polyclonal targets BRD4

Target Organism: human

Clone ID: BL-149-2H5

Antibody ID: AB_2631885

Vendor: Thermo Fisher Scientific

Catalog Number: A700-004

Record Creation Time: 20231110T033003+0000

Record Last Update: 20260831T225729+0000

Ratings and Alerts

No rating or validation information has been found for BRD4 Recombinant Monoclonal Antibody [BL-149-2H5].

Warning: Discontinued at Thermo Fisher Scientific
Discontinued; Applications: ICC (1:25-1:250), IP (5-20 µL/0.5 mg lysate), IHC (1:25-1:250), ChIP-seq (10-40 µL/30 µg chromatin), WB (1:1,000), IF (1:25-1:250)

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen B, et al. (2026) BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes. Molecular cell, 86(5), 917.

Caksa S, et al. (2025) Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. Cancer research.

Serebrenik YV, et al. (2024) Pooled endogenous protein tagging and recruitment for systematic profiling of protein function. Cell genomics, 4(10), 100651.

Chen H, et al. (2023) BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation. Molecular cancer research : MCR, 21(2), 91.

Chen Z, et al. (2020) Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling. JCI insight, 5(20).

Federation AJ, et al. (2020) Highly Parallel Quantification and Compartment Localization of Transcription Factors and Nuclear Proteins. Cell reports, 30(8), 2463.